Pharmaceutical / Drug Definition :
Selectively blocks binding of angiotensin II to specific tissue receptors in vascular smooth muscle and adrenal gland. This action blocks vasoconstrictive effects of renin-angiotensin system as well as aldosterone release, thereby reducing blood pressure and possibly preventing vascular remodeling related to arteriosclerosis.
In the United States, Olmesartan Medoxomil is regulated by the U.S. Food and Drug Administration (FDA). FDA has specific requirements regarding the registration and listing of Olmesartan Medoxomil.
FDA Label Requirements and Exceptions
FDA Import Information
Olmesartan Medoxomil (Olmesartan Medoxomil Entry Refusal)
General U.S. Food and Drug Administration Guidelines for:
- Manufacturers Olmesartan Medoxomil (Olmesartan Medoxomil Suppliers)
- Processors Olmesartan Medoxomil
- Repackers Olmesartan Medoxomil
- Relabelers Olmesartan Medoxomil
- Exporters Olmesartan Medoxomil
- Importers Olmesartan Medoxomil
For more information about Olmesartan Medoxomil, simply click below:
U.S. FDA Regulations:
U.S. FDA Regulation: 21 C.F.R. Part 207
Registrar Corp assists businesses with U.S. FDA compliance. Certificates of Registration issued by Registrar Corp provide confirmation to industry that you are fulfilling U.S. FDA registration requirements. U.S. FDA does not issue or recognize Certificates of Registration. Registrar Corp is not affiliated with the U.S. Food and Drug Administration.